Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 trial of VY-AADC01 in the patients with advanced Parkinson's disease

Next Previous
X
Search
Trial Profile

Phase 2/3 trial of VY-AADC01 in the patients with advanced Parkinson's disease

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 05 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ezaladcigene resoparvovec (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Voyager Therapeutics

    • Most Recent Events

    • 29 Jan 2019 According to a Neurocrine Biosciences media release, the company entered into a strategic collaboration with Voyager Therapeutics. Under the terms of the agreement the company will fund the phase II/III pivotal program for VY-AADC.
    • 10 May 2018 According to a Voyager Therapeutics media release, Anticipated approval of IRB submissions along with feedback from a planned Type C meeting with the FDA, can allow for first patient dosing expected in the middle of this year.
    • 23 Jan 2018 According to a Voyager Therapeutics media release, the US FDA has cleared the Investigational New Drug (IND) application for VY-AADC.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top